Ceftazidime
(Fortaz, Ceptaz, Tazicef, Tazidime)
|
Category:
Description:
Indications:
-
Lower respiratory tract infections (P.
aeruginosa and other Pseudomanas species,
H. influenzae, Klebsiella species, S.
pneumoniae, S. aureus, E.
coli, Serratia species,
Enterobacter species, P.
mirabilis, Citrobacter species)
-
Urinary tract infections (E. coli, Klebsiella species, Proteus
species, Enterobacter species,
P. aeruginosa)
-
Skin, bone and joint infections (P. aeruginosa, Enterobacter species, E. coli, Proteus species, Klebsiella
species, Serratia species,
E. coli, S. aureus, S. pyogenes)
-
Intra-abdominal infections (E. coli, Klebsiella species,
S. aureus, Bacteroides species, polymicrobial infections caused by
aerobic and anaerobic organisms)
-
Bacterial septicemia (P. aeruginosa, Klebsiella species, H. influenzae, E. coli, Serratia species, S. pneumoniae, S. aureus)
-
Gynecological
infections (E. coli)
-
CNS
infections (H. influenzae, N.
meningitidis)
Contraindications:
Precautions:
Adverse
Reactions (Side Effects):
-
Hypersensitivity
reactions
-
Gastrointestinal:
nausea, vomiting, diarrhea
-
Vaginitis
|
Dosage:
-
Administered
by injection (IM and IV)
-
Adults:
-
uncomplicated urinary tract infections:
-
complicated urinary tract infections:
-
meningitis:
-
uncomplicated pneumonia, mild skin
infections:
-
bone and joint infections:
-
meningitis:
-
severe, life-threatening infections:
-
pseudomonal lung infections:
-
Infants and Children (1 month – 1 year)
-
Neonates (0-4 weeks):
|
Source:
Operational Medicine 2001, Health
Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau
of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington,
D.C., 20372-5300
|